# AVITA Medical to Announce Second Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/RCEL/avita-medical-to-announce-second-quarter-2026-financial-results-8e67c186
Ticker: RCEL
Company: Avita Medical
Source: Avita Medical
Published: 2026-07-14 20:05 EST
## Summary

AVITA Medical will report second quarter 2026 financial results after the close of the U.S. financial markets on Thursday, August 6, 2026. ...

## Article Body
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its second quarter 2026 financial results after the close of the U.S. financial markets on Thursday, August 6, 2026. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, August 7, 2026, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights.

Second Quarter 2026 Webcast and Conference Call Information

To listen to the conference call webcast, please register and join using the following link: https://edge.media-server.com/mmc/p/j4xwf8nv .

To participate in the live earnings conference call, please register in advance to receive dial-in details and a personal PIN using the following link: https://register-conf.media-server.com/register/BI599cce9ea71e49dcb7e4c36b4612ff99 .

For those unable to participate in the live broadcast, a replay will be available on the Events page of the Company’s investor relations website at: https://ir.avitamedical.com/events-and-presentations .

About AVITA Medical, Inc.

AVITA Medical ® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is RECELL ® , approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx ® , an AVITA Medical-branded collagen-based dermal matrix, and the exclusive rights to manufacture, market, sell, and distribute PermeaDerm ® , a biosynthetic wound matrix.

In international markets, RECELL is approved to promote skin healing in a wide range of applications, including thermal burn and trauma wounds. RECELL and RECELL GO ® are CE-marked in Europe, have TGA certification in Australia, and are listed with Medsafe in New Zealand; RECELL is PMDA-approved in Japan.

To learn more, visit www.avitamedical.com.

Investor & Media Contact: Ben Atkins Phone +1-805 341 1571 investor@avitamedical.com media@avitamedical.com

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
## Recent Company News
- 2026-07-14 20:05 EST — [AVITA Medical to Announce Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RCEL/avita-medical-to-announce-second-quarter-2026-financial-results-8e67c186) — Source: Avita Medical
- 2026-06-18 12:40 EST — [AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting](https://biopharmsignal.com/news/RCEL/avita-medical-highlights-first-u-k-clinical-experience-with-recell-go-at-british-188835be) — Source: Avita Medical
- 2026-05-17 22:00 EST — [AVITA Medical to Host Investor Webinar Briefing](https://biopharmsignal.com/news/RCEL/avita-medical-to-host-investor-webinar-briefing-fc878ee8) — Source: Avita Medical
- 2026-05-14 20:05 EST — [AVITA Medical Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/RCEL/avita-medical-reports-first-quarter-2026-financial-results-fc8fc795) — Source: Avita Medical
- 2026-04-30 12:50 EST — [AVITA Medical Names Cary Vance as Chief Executive Officer](https://biopharmsignal.com/news/RCEL/avita-medical-names-cary-vance-as-chief-executive-officer-9d7f5bda) — Source: Avita Medical
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)